Therapeutic agent for motor disorders
Provided are an agent for the treatment and/or prophylaxis of a movement disorder, the agent for the treatment and/or prophylaxis wherein the movement disorder is extrapyramidal syndrome, the agent for the treatment and/or prophylaxis wherein the movement disorder is bradykinesia, gait disturbance, dystonia, dyskinesia or tardive dyskinesia, the agent for the treatment and/or prophylaxis wherein the movement disorder is a side effect of L-DOPA and/or dopamine agonist therapy, and the like, each containing a thiazole derivative represented by the formula (I) wherein R 1 represents aryl and the like, and R 2 represents pyridyl or the like, or a pharmaceutically acceptable salt thereof as an active ingredient.
1. A method of treating and/or preventing progression of a motor complication caused by L-DOPA and/or dopamine agonist therapy, comprising the steps of:
administering to a patient undergoing L-DOPA and/or dopamine agonist therapy an effective amount of a thiazole derivative represented by formula (IC)
or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 , wherein the motor complication is wearing-off phenomenon.
3. The method according to claim 1 , wherein the motor complication is on-off fluctuation.
4. The method according to claim 1 , wherein said motor complication is caused by L-DOPA therapy and said patient is undergoing L-DOPA therapy.
5. The method according to claim 1 , wherein said motor complication is caused by dopamine agonist therapy and said patient is undergoing dopamine agonist therapy.
6. The method according to claim 2 , wherein said motor complication is caused by L-DOPA therapy and said patient is undergoing L-DOPA therapy.
7. The method according to claim 2 , wherein said motor complication is caused by dopamine agonist therapy and said patient is undergoing dopamine agonist therapy.
8. The method according to claim 3 , wherein said motor complication is caused by L-DOPA therapy and said patient is undergoing L-DOPA therapy.
9. The method according to claim 3 , wherein said motor complication is caused by dopamine agonist therapy and said patient is undergoing dopamine agonist therapy.